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Summary
The vasculature in the angiogenic stages of a mouse model of pancreatic islet carcinogenesis was profiled in vivo with
phage libraries that display short peptides. We characterized seven peptides distinguished by their differential homing to
angiogenic progenitors, solid tumors, or both. None homed appreciably to normal pancreatic islets or other organs. Five
peptides selectively homed to neoplastic lesions in the pancreas and not to islet  cell tumors growing subcutaneously,
xenotransplant tumors from a human cancer cell line, or an endogenously arising squamous cell tumor of the skin. Three
peptides with distinctive homing to angiogenic islets, tumors, or both colocalized with markers that identify endothelial
cells or pericytes. One peptide is homologous with pro-PDGF-B, which is expressed in endothelial cells, while its receptor
is expressed in pericytes.
Introduction studies have shown that a number of genes are upregulated
during the transition from normal to tumor blood vessels, includ-
Angiogenesis, the formation of new blood vessels, is essential ing the integrins v3, v5, and 51; several matrix metallo-
for tumor growth. The transition from normal to neoplastic vas- proteinases; and various endothelial growth factor receptors
culature during tumorigenesis has been termed the “angiogenic (Hanahan and Folkman, 1996; Ruoslahti, 2002). Recently, St.
switch,” and both positive and negative regulators of the switch Croix et al. further showed, using a comparative RNA expression
have been identified (Hanahan and Folkman, 1996). The vascular profiling technology (SAGE), that a number of genes or EST’s
anatomy of tumors is typically distinct from that of normal tis- were selectively expressed or upregulated in the tumor endothe-
sues (Carmeliet and Jain, 2000). In contrast to their normal lium of human colorectal cancer, relative to the corresponding
counterparts, tumor vessels are tortuous and dilated and show normal colonic vasculature (St. Croix et al., 2000). This approach
reduced vessel integrity. Tumor vessels often have numerous
relied on substantive differences in gene expression to identifyfenestrae or discontinuities, loose interendothelial junctions, and
tumor-specific endothelial markers, which will likely only reveala discontinuous or absent basement membrane, collectively
a subset of alterations that distinguish normal and tumor bloodresulting in vessel leakiness (Carmeliet and Jain, 2000; Hashi-
vessels. Specific binding of phage from libraries that can displayzume et al., 2000).
more than a billion random peptide sequences offers a comple-We are only beginning to understand the molecular events
mentary approach for comparative screening. In vivo phageunderlying the pronounced abnormalities evident in the angio-
genic vasculature of tumors and progenitor lesions. Previous display screening has proven to be a powerful method for un-
S I G N I F I C A N C E
While there is abundant evidence that tumor vasculature is functionally and morphologically aberrant, we show herein using a
peptide epitope profiling technology that the angiogenic vasculature in premalignant lesions is distinguishable from normal as well
as tumor vessels in a model of multistage tumorigenesis. Moreover, both angiogenic progenitor and tumor vessels in the pancreas
have molecular signatures distinct from tumors growing in or under the skin, even of the analogous cell type. The stage and organ
specificities of particular homing peptides may prove instructive about mechanisms regulating the neovasculature in different
pathways of tumorigenesis, suggest means to detect and distinguish premalignant and malignant lesions noninvasively, and predict
differential sensitivity to therapeutic agents targeting angiogenesis.
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Figure 1. Isolation of stage-specific phage using ex vivo and in vivo phage display
A: Ex vivo screening on cells derived from RIP1-Tag2 angiogenic islets or tumors using the CX7C peptide library displayed on T7 phage. The enriched phage
pools were used for subsequent in vivo homing to RIP1-Tag2 angiogenic islets (three rounds of selection) (B) and tumors (two rounds of selection) (C). D:
In vivo homing of individual phage to RIP1-Tag2 angiogenic islets and tumors.
covering differences among individual vascular beds in normal We used a prototypical mouse model of multistage tumori-
organs (Pasqualini and Ruoslahti, 1996; Rajotte et al., 1998) genesis, the RIP1-Tag2 transgenic model of islet cell carcinoma
and has also yielded peptides that specifically home to blood (Hanahan, 1985), to address our hypothesis that the vasculature
vessels or lymphatics in tumors (Arap et al., 1998; Laakkonen of pre-neoplastic lesions differs from that of established tumors.
et al., 2002; Porkka et al., 2002). The targets for these peptides RIP1-Tag2 transgenic mice express the SV40 T antigens (Tag)
in blood vessels include the v3 and v5 integrins (Arap et under the control of the insulin gene promoter, which elicits the
al., 1998) and aminopeptidase N (Pasqualini et al., 2000). sequential development of tumors in the islets of Langerhans
In this and a companion study (Hoffman et al., 2003 [this over a period of 12–14 weeks. Hyperplastic islets begin to ap-
issue of Cancer Cell]), we set out to use phage-display profiling pear at around 4 weeks of age, and angiogenesis is activated
to ask whether additional levels of neoplastic vascular special- a few weeks later in a subset of the hyperplastic islets, producing
ization might exist in tumor development. We sought to distin-
angiogenic (dysplastic) islets (Bergers et al., 1998; Folkman et
guish the vessels of premalignant angiogenic lesions from those
al., 1989). Solid tumors form beginning at 9 to 10 weeks, initiallyof angiogenic solid tumors and to examine whether differences
presenting as small nodules that grow and progress to largeexist between angiogenic vessels of tumors developing in differ-
islet tumors with well-defined margins, as well as two classesent organs. Previous studies have profiled differences between
of invasive carcinoma (Lopez and Hanahan, 2002). We set outnormal blood vessels and the vasculature of transplanted tu-
to identify stage-specific molecular markers accessible via themors in immunodeficient mice. Unlike these transplanted tu-
circulation, either on the surface of endothelial cells, their peri-mors, transgenic tumor models provide an opportunity to exam-
endothelial support cells (pericytes and smooth muscle cells),ine pre-neoplastic changes unfolding in different organs in a
more physiologically relevant microenvironment. or even tumor cells themselves (as a result of the hemorrhagic,
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leaky angiogenic vasculature). We successfully selected phage (KAA, KAR, and VGVG), angiogenic islet-selective phage (RSR
and EYQ), and phage that home to both types of angiogenicpools that homed preferentially to different stages during RIP1-
Tag2 tumorigenesis. In addition to “pan-angiogenic” markers lesions (VGVA and RGR). Some of the selected peptides that share
similar peptide motifs also display similar homing patterns. Forshared by many types of tumors, we identified vascular target
molecules that are characteristic of this tumor’s tissue of origin example, KAA and KAR (CKAAKNK and CKGAKAR XBXXBXB,
where B represents basic residues and X denotes unchargedand are not expressed in the vessels of several tumor types
growing in or under the skin. We have begun to investigate the residues) both preferentially home to tumors over angiogenic
islets. However, other related peptides such as RGR and RSRbinding partners for these peptides and present evidence link-
ing one peptide to a vascular signaling circuit involving PDGF (CRGRRST and CRSRKG XBXBBX) have quite different hom-
ing capabilities. Interestingly, all of these peptides are distinctligands expressed in endothelial cells and their receptor
PDGFR, expressed in pericytes of the angiogenic vasculature. from those found previously in phage display screens of trans-
plant tumors (Arap et al., 1998; Laakkonen et al., 2002; Porkka
et al., 2002).Results
Isolation of stage-specific phage from RIP1-Tag2 mice Stage-specific homing of fluorescein-conjugated
peptidesRIP1-Tag2 mice develop multifocal angiogenic islet progenitors
and then solid tumors in a stepwise manner, such that at 12 To confirm that the selective phage homing was due to the
displayed peptide sequences, we studied the localization ofweeks of age, each mouse will typically have approximately
50 angiogenic islets and 2–6 small tumors. This circumstance fluorescein-conjugated peptides after intravenous injection; one
peptide from each homing class was selected for detailed analy-allowed us to use 12-week-old mice to select for phage binding
to angiogenic islet progenitors and/or tumors in the same sis. We used 8-week-old RIP1-Tag2 mice to examine peptide
localization during the angiogenic switch and 12-week-oldmouse. In order to enrich for phage that bind to RIP1-Tag2
target cells (endothelial, perivascular, and tumor), we included RIP1-Tag2 mice to visualize both angiogenic islets and tumors.
The observed peptide localization profiles in each casea pre-selection step (Laakkonen et al., 2002; Porkka et al., 2002)
on cell suspensions prepared from pancreatic lesions. Two closely mimicked that of the cognate phage, as shown in Figure
1D, with each peptide falling into the same of the three homingrounds of ex vivo selection from a CX7C peptide library on
cell suspensions from angiogenic islets or solid tumors yielded classes. Figure 2 illustrates the peptide localization for these
three representative fluorescein-conjugated peptides: RSR (an-phage pools that bound 7- to 8-fold over a control, nonrecombi-
nant phage to their respective target cells (Figure 1A). These giogenic-selective), KAA (tumor-selective), and RGR (angio-
genic- and tumor-homing). RSR shows abundant accumulationenriched phage pools were used in subsequent in vivo rounds
to select for phage that would home specifically to either angio- in RIP1-Tag2 angiogenic islets (Figure 2B) but little or no local-
ization in tumors (Figure 2C) or normal islets (Figure 2A). KAAgenic islets or tumors in RIP1-Tag2 mice.
Three rounds of in vivo selection on angiogenic islets re- shows abundant localization in RIP1-Tag2 tumors (Figure 2F)
but little or no localization in angiogenic islets (Figure 2E) orsulted in a phage pool that selectively homed to angiogenic
islets. The homing to the islets was 7-fold higher than to tumors normal islets (Figure 2D). Finally, RGR localizes in both RIP1-
Tag2 angiogenic islets (Figure 2H) and tumors (Figure 2I) butin the same mouse (Figure 1B). There was no homing to control
organs. The tumor selection yielded a pool that showed an there is little or no peptide in normal islets (Figure 2G). It was
somewhat unexpected that RSR, which was selected from the8-fold preference for tumors versus angiogenic islets in the
same mouse following two rounds of in vivo selection (Figure tumor phage screening, preferentially bound to angiogenic is-
lets. It seems that the epitope this peptide binds to is present1C).
Sequencing of phage from the selected pools identified a both in tumors and angiogenic islets, but is more abundant in
angiogenic islets. This result could also be indicative of thenumber of peptide sequences that were represented more than
once, and these were tested for their ability to bind cell suspen- heterogeneity of the pools of angiogenic islets or tumors isolated
by gross examination, in which there are multiple lesions ofsions prepared from angiogenic islets and tumors. Six of the
phage selected for further analysis were from the tumor screen differing grades within each group. Hence, a gross selection
of the tumor pool may in fact include some large, advanced(referred to as KAA, RGR, RSR, VGVA, VGVG, and KAR), and
one (EYQ) was picked from the angiogenic screen. Peptide angiogenic islets that can only be definitively distinguished by
histological grading, which was performed in conjunction withsequences corresponding to each of these peptide motifs are
shown in Table 1. All of these peptides are linear, although the peptide homing to the different lesions.
Homing of the peptides to the pancreatic islet lesions wasthe phage library used here (CX7C) was designed to express
peptides cyclized by a covalent bond between two cysteine specific: little or no homing was detected in normal islets, brain,
liver, lung, and spleen (Figures 2K and 2L and data not shown).residues. However, a library of this design does contain a minor-
ity of linear peptides. A stop codon occurring within the random Fluorescence was detected in kidney, presumably as a result
of uptake from glomerular filtrate (Figure 2J). Representativeinsert will cause truncation of the peptide, and a frameshift
mutation frequently changes the second cysteine into valine. It figures of control tissues from a RIP1-Tag2 mouse injected
with fluorescein-conjugated RGR peptide are shown in Figuresmay be that the target molecules in the RIP1-Tag2 tumors se-
lected for linear peptides. In the companion study (Hoffman et 2J–2L. A similar absence of fluorescence in control tissues was
observed for all other injected peptides (data not shown). Inal., 2003), the same library yielded cyclic homing peptides. The
RIP1-Tag2 homing phage fall into three classes based on their addition, control peptides did not show specific homing to any
of the RIP1-Tag2 lesional stages or to a number of normalhoming either to angiogenic islets or to tumors in vivo (Figure
1D) and their ex vivo binding patterns: tumor-selective phage tissues.
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Figure 2. Stage-specific homing of fluorescein-
conjugated peptides in RIP1-Tag2 model
Visualization of an angiogenic islet-selective
peptide (RSR) homing is shown in normal islet
(A), angiogenic islet (B), and tumor (C). Homing
profiles are also shown for a tumor-selective pep-
tide (KAA) to normal islet (D), angiogenic islet (E),
and tumor (F), as well as of a peptide (RGR) that
homes to both angiogenic islets and tumors (G,
normal islet; H, angiogenic islet; and I, tumor).
Control tissues (J, kidney; K, brain; and L, liver)
from a RIP1-Tag2 mouse injected with fluores-
cein-conjugated RGR peptide are also pre-
sented. Similar absence of fluorescence in con-
trol tissues was observed for all other injected
peptides, indicative of a lack of specific homing.
The scale bar corresponds to 50 M.
Fluorescein-conjugated peptides colocalize thelial cell and pericyte markers, indicating that each homes to
with vascular markers and binds moieties associated with both cell types (Figure 3
We reasoned that intravenous administration of the phage librar- and data not shown). Again, there was no colocalization of these
ies would select for phage carrying peptides that bind to endo- peptides with those same markers in the adjacent exocrine
thelial molecules specific for the target vasculature. The expec- pancreas or in normal pancreatic islets; tissue sections stained
tation of endothelial selectivity is based upon the preferential with MECA32 and NG2 showed some colocalization, consistent
exposure of phage to luminal cells of the vasculature, as well with the proximity of endothelial cells and pericytes (Figures
as the appreciable size of the phage and the short time the 3S–3U).
phage are allowed to circulate (Pasqualini and Ruoslahti, 1996). The apparent homing of peptides representing all three
In order to test this expectation, tissues were collected following classes of stage specificity to both pericytes and endothelial
i.v. infusion with the various fluorescein-conjugated peptides, cells was unexpected. It may be pertinent that the RIP1-Tag2
sectioned, and evaluated with endothelial cell markers. The pri- tumor vasculature is known to be leaky, as evidenced by exten-
mary analysis involved immunostaining with a mouse pan-endo-
sive microhemorrhaging (Parangi et al., 1995) and morphometricthelial cell antigen (MECA32) antibody that recognizes a dimer
analysis (Hashizume et al., 2000; Morikawa et al., 2002; Thurstonof 50–55 kDa protein subunits present on all endothelial cells
et al., 1998), such that the circulating phage pool likely had(Hallman et al., 1995; Leppink et al., 1989) (Figures 3B, 3C,
access to the extraluminal vascular microenvironment, where3H, 3I, 3N, and 3O). Additional analyses (not shown) involved
receptors on pericytes and in the extracellular matrix could beimmunostaining to reveal CD31/PECAM or systemic infusion of
accessible. It is known that the vasculature of both angiogenica fluorescent-labeled lectin that binds to the endothelial lumen.
islets and tumors is leaky (Morikawa et al., 2002). However,In addition, tissue sections from peptide-infused mice were
reciprocal homing of the peptides that recognize the angiogenicstained with an antibody recognizing NG2, a marker of the
islet but not tumor vessels, and vice versa, excludes the possibil-neovascular pericytes (Schlingemann et al., 1990, 1991) (Figures
ity that the recognition of angiogenic islet versus tumor vessels3E, 3F, 3K, 3L, 3Q, and 3R). Remarkably, all three peptides
(RSR, KAA, and RGR) show some colocalization both with endo- would simply be caused by differences in the leakiness of the
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vessels. The ex vivo pre-selection step we used to enrich for
RIP1-Tag2-specific targets may have similarly selected for non-
luminal endothelial binding partners, but it should be empha-
sized that any peptide selected ex vivo must also have been
accessible via the circulation during the in vivo selections. Con-
sistent with this logic, phage-displaying peptides that bind to
the pericyte marker, NG2, have previously been shown to home
to a transplant tumor in vivo (Burg et al., 1999).
Specificity of in vivo homing to islet
tumors in the pancreas
Selection of phage that home to the vasculature of neoplastic
lesions in RIP1-Tag2 mice can be envisioned to identify two
classes of peptides: those whose cognate receptors are specific
to angiogenic islets and/or tumors in the pancreas and those
that also home to the angiogenic vasculature in other tumor
types. Therefore, we asked whether phage and peptides se-
lected in pancreatic neoplasias would home to two different
transplant tumors growing subcutaneously or to de novo skin
tumors induced in another transgenic mouse model.
TC3 transplant tumors arise following subcutaneous inoc-
ulation of nude mice with cultured islet tumor-derived (TC3)
cells (Efrat et al., 1988), allowing the study of islet tumors and
their vasculature outside of their natural environment in the
pancreas. Because the vasculature of a subcutaneously grown
TC3 tumor derives from skin, we also tested another subcuta-
neous transplant tumor, arising from inoculation of the MDA-
MB-435 human breast carcinoma cell line. Finally, K14-HPV16
mice, another well-studied transgenic mouse model of cancer
that develop tumors of the squamous epithelial cells of the
skin (Arbeit et al., 1994; Coussens et al., 1996), allowed us to
compare RIP1-Tag2 islet tumors to a tumor with similar
multistage pathogenesis arising in a different tissue. The relative
homing efficiencies in the various tumor models of the phage
from the RIP1-Tag2 tumor screen fall broadly into two catego-
ries: those that selectively home to RIP1-Tag2 tumors (KAA,
RGR, VGVA) and those that show a more general homing to
other tumors in addition to RIP1-Tag2 (VGVG, KAR) (Figure 4A).
The phage homing data were supported by i.v. injection of
fluorescein-conjugated peptides corresponding to the phage.
Results for the three representative peptides are summarized in
Figure 4B, and an example of the tissue fluorescence produced
following injection of the KAR peptide in different tumors is
shown in Figures 4C–4E.
Homing during non-tumor angiogenesis was examined us-
ing angiogenesis in subcutaneously implanted matrigel plugs.
All peptides except one showed no homing to the matrigel
plugs. The RGR peptide appeared in a punctate manner in some
Figure 3. Colocalization of fluorescein-conjugated peptides with vascular blood vessels. However, the intensity was much lower and the
markers in RIP1-Tag2 islet lesions pattern quite different than in RIP-Tag lesions (data not shown).
RSR peptide localization in an angiogenic islet is shown in (A) and (D) This indicates that this set of peptides are selective for neovas-
(green), while co-staining for MECA32 (red) and the merge are shown in cularization during tumorigenesis and are not general markers
(B) and (C). Co-staining for NG2 (red) is shown in (E), with the merge in (F).
of neovessel formation.KAA peptide localization in a tumor is shown in (G) and (J) (green), while
co-staining for MECA32 (red) and the merge are shown in (H) and (I). Co-
staining for NG2 (red) is shown in (K), with the merge in (L). RGR peptide Identification of candidate vascular receptors
localization in an angiogenic islet is shown in (M) and (P) (green), while co- The set of peptides homing to angiogenic neoplasias in the
staining for MECA32 (red) and the merge are shown in (N) and (O). Co-
pancreas were applied to database searches, seeking to identifystaining for NG2 (red) is shown in (Q), with the merge in (R). Staining for
mouse proteins with sequences homologous to the peptides.endothelial cells (MECA32) (S) and pericytes (NG2) (T) in tumor sections
demonstrated their close association (U). Scale bar: 10 m. Table 1 lists candidate proteins with such homologies that were
deemed to be of interest. In theory, these proteins could corre-
spond to putative ligands mimicked by the phage-displayed
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Figure 4. Evaluation of the neoplastic specificity of selected homing phage and peptides
A: Bar graph showing homing efficiency of individual phage to a pancreatic islet tumor in a RIP1-Tag2 mouse, a TC3-derived subcutaneous transplant
tumor in a nude mouse, and a squamous cell carcinoma in a K14-HPV16 mouse.
B: Table summarizing the relative homing of fluorescein-conjugated peptides to different tumor models.  indicates strong homing, as revealed by the
fluorescent intensity of i.v. injected peptide,  indicates moderate homing,  indicates weak homing, - indicates absence of homing. Representative
images of fluorescein-conjugated KAR peptide homing to a RIP1-Tag2 pancreatic islet tumor (C), a TC3 subcutaneous tumor (D), and an MDA subcutaneous
tumor (E) are also shown. Magnification 200.
peptides. Many of the candidate proteins have been previously quences in two cell surface receptors, fibroblast growth factor
receptor 1 (FGFR1) and Tie-1, were revealed by homologyassociated with the vasculature. One protein, collagen XII, was
found to share homology with two peptides: KAR (CKGAKAR) searching, as phage-displayed peptides have traditionally been
thought to mimic ligands not receptors. However, in the caseand VGVA (FRVGVADV), though in different structural domains.
It is interesting to note that collagen XII was also identified by of FGFR1, the particular peptide sequence (YQLDV) has been
reported to be in the ligand binding domain D2 (Plotnikov et al.,gene expression profiling as a gene that is overexpressed in
tumor endothelial cells (St. Croix et al., 2000; and http://mendel. 1999), suggesting the possibility that the phage displaying this
peptide may in fact be binding to FGFR1 ligands, i.e., the fibro-imp.unvie.ac.at/SEQUENCES/TEMS/mainpgs/temtable.html).
It was somewhat surprising that homologies to peptide se- blast growth factors (FGFs). It is well known that many of the
Table 1. Candidate mouse proteins sharing motifs with homing peptides
Peptide Peptide sequence Extended motif Mouse protein with the motif Accession number
RGR CRGRRST RGRRS PDGF-B P31240
RGRR Stromal interaction molecule 2 Q9P246
RSR CRSRKG CRSR-G Cadherin EGF LAG receptor 1 O35161
KAA CKAAKNK CKA-K WNT-2 NPO76142
KAR CKGAKAR CKGAKA Collagen XII Q60847
AKAR Collagen XII Q60847
GAKAR Claudin 9 Q9ZOS7
VGVA FRVGVADV F-VGVADV Collagen XII Q60847
RVGV Collagen XII Q60847
EYQ CEYQLDVE CEYQL Semaphorin 4C Q64151
YQLDV FGFR1 P16092
YQLDV Tie-1 Q06806
Peptides were analyzed using a BLAST (NCBI) search against the SWISSPROT database, using the option for short nearly exact matches, to identify mouse
proteins with homologous sequences.
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heparin binding FGFs are sequestered in the extracellular matrix
and basement membrane by binding to heparan sulfate proteo-
glycans (Ornitz and Itoh, 2001), which is consistent with phage
homing to these FGF depots in vivo. As the Tie-1 receptor is
an orphan receptor tyrosine kinase, ligand binding information
is not currently available; however, the peptide sequence homol-
ogy is in the extracellular domain (Sato et al., 1993).
Another provocative homology was seen for the RGR pep-
tide (CRGRRST), which is contained within the B chain of the
pro-form of platelet-derived growth factor (PDGF-B), a known
ligand for the transmembrane receptor tyrosine kinase PDGFR.
The RGR sequence homology (RGRRS) spans the pro-peptide
cleavage site of pro-PDGF-B (Johnsson et al., 1984). To investi-
gate the hypothesis that the RGR peptide was homing to
PDGFR by virtue of this homology, we transfected 293T cells
with a fusion gene designed to overexpress PDGFR. The bind-
ing of RGR phage was 20-fold more efficient to PDGFR-trans-
fected cells than nontransfected cells. In contrast, no binding
above the background was detected toward cells transfected
with vascular endothelial growth factor receptor 2 (VEGFR2)
(Figure 5A). Moreover, when we tested the RSR phage, which
has a peptide sequence similar to RGR, no specific binding
was observed either to PDGFR- or VEGFR2-transfected cells
(Figure 5A). The association of RGR with PDGFR was further
substantiated when intravenously injected fluorescein-conju-
gated RGR peptide was shown to colocalize with PDGFR,
visualized by subsequent immunostaining of tissue sections
from RIP1-Tag2 tumors. Merging of the RGR-FITC image (Figure
5B, panel a) with the antibody staining for PDGFR (Figure 5B,
panel b) revealed almost complete colocalization (Figure 5B,
panels c and d).
Discussion
Figure 5. PDGFR is a candidate receptor for RGR peptideWe set out in this and the companion study (Hoffman et al.,
A: Bar graph showing binding of RGR or RSR phage to 293T cells transfected2003) to characterize the vasculature during the discrete stages
with either the PDGFR, the related VEGFR2, or nontransfected cells. Y axisof organ-specific carcinogenesis, using a profiling technology
fold over nonrecombinant phage.based on peptide libraries displayed on the surface of bacterio-
B: Colocalization of fluorescein-conjugated RGR peptide (a, green) with
phage. Phage that display a peptide with an appropriate binding the PDGFR antibody (b, red) and merged images (c and d) in RIP1-Tag2.
specificity home via the circulation to the site of binding affinity. Magnification 400.
As such, phage profiling can reveal differences in the composi-
tion and properties of the vasculature of different organs and
pathological lesions. Using as a target the RIP1-Tag2 mouse
model of multistage tumorigenesis involving the pancreatic is- and Kohn, 2001). As developing neoplasias activate angiogen-
lets of Langerhans, we have identified peptides that discriminate esis and recruit a neovasculature from the surrounding tissue
between the vasculature of the premalignant angiogenic islets microvascular bed, the organ microenvironment may influence
and the fully developed tumors. Most of the identified homing the morphology and physiology of the tumor neovasculature.
peptides appear to selectively detect vascular changes induced Evidence in support of organ-specific differences has come, for
during tumorigenesis in the endocrine pancreas, but not in other example, by comparing permeability in the vessels of transplant
tumors growing in or under the skin. Remarkably, three peptides tumors as a function both of tumor type and the host tissue
representing one of the distinctive homing classes (to angio-
site (Hobbs et al., 1998; Roberts et al., 1998).
genic progenitors, to tumors, or to both) each colocalized with
We asked whether tumors arising in their natural microenvi-markers separately identifying endothelial cells and pericytes in
ronment are different from those developing in another “foreign”the angiogenic lesions. The sequences of the homing peptides
location by comparing endogenously arising RIP1-Tag2 tumorssuggest candidate proteins containing homologous sequences
in the pancreas with TC3 cell-derived tumors grown subcuta-that are mimicked by peptide binding to the angiogenic vascu-
neously (the TC3 cell line was established from a RIP1-Tag2lature.
pancreatic islet tumor; Efrat et al., 1988). The results from both
phage and peptide binding (Figure 4 and data not shown) indi-Insights into organ-specific differences
cate that some phage/peptides home to TC3 subcutaneousin neoplastic vasculature
tumors in addition to RIP1-Tag2 endogenous tumors, albeitThe influence of tissue microenvironment in tumor development
is increasingly appreciated (Coussens and Werb, 2002; Liotta less efficiently (e.g., VGVG). However, most of the other phage/
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peptides do not show any appreciable homing to TC3 tumors sion and/or signaling. The most compelling evidence comes
from overexpressing PDGFR in cultured cells. There was aby comparison to RIP1-Tag2 tumors (e.g., KAA and VGVA),
supporting the predominant role of the tissue microenvironment striking increase in the binding of the RGR phage to cells trans-
fected with PDGFR, whereas transfection with a structurallyin influencing some of the receptors that are displayed on the
cell surface. related receptor tyrosine kinase, VEGFR2, had no effect on the
binding. Moreover, systemically infused RGR colocalizes withSimilar results were found for the two other tumor types we
studied: squamous cell carcinomas of the epidermis arising virtually all of the PDGFRdetected by immunostaining in angio-
genic islets and tumors. Both lines of evidence support thein K14-HPV16 transgenic mice and subcutaneous xenograft
tumors of the human MDA-MB-435 breast cancer cell line. KAR model that RGR binds to PDGFR. There are, however, other
data that complicate this simple conclusion. First, RGR colocal-and VGVG were the only phage/peptides that homed apprecia-
bly to these models, whereas the other peptides showed a izes not only with a pericyte marker, NG2, consistent with
PDGFR expression in pericytes, but also with an endothelialsimilar lack of homing, as for TC3 tumors. Thus, the majority
of phage-displayed and soluble peptides homed selectively to cell marker, MECA32, indicative of homing to endothelial cells
(which do not typically express PDGFR—see Bergers et al.,the tumor vasculature of RIP1-Tag2 tumors arising in their natu-
ral environment in the endocrine pancreas, showing little affinity 2003). Second, the RGR peptide sequence overlaps the pro-
peptide processing site and is thus only partially representedfor tumors growing subcutaneously or in the skin itself. By con-
trast, in the aforementioned study of tumor endothelial genes in mature PDGF-B ligand; moreover, the sequences for PDGF
homo- and heterodimerization and for receptor binding are notrevealed by expression profiling (St. Croix et al., 2000), a number
of the tumor-specific endothelial genes identified as upregulated at the N terminus of the mature ligand (Clements et al., 1991;
Heldin and Westermark, 1999; Ostman et al., 1991). Thus it is notin a colorectal cancer screen were also found in the tumor
endothelium of other cancers (lung, brain, pancreas, and breast clear how RGR might bind either to PDGF ligands or receptors.
These data lead us to suggest that RGR mimics a protein-primary tumors; and a colorectal metastasis to the liver). Our
method has clearly revealed a partially overlapping but distinc- protein interaction site in pro-PDGF-B that mediates its specific
homing and mimics bona fide associations of pro-PDGF-B. Onetive set of markers. These results support the existence of both
tumor-specific and tumor-generic vascular markers and may possible association for RGR is either with PDGFR itself or
with a protein induced by its expression, given the enhancedhave implications for interpretation of data forthcoming from
xenograft tumor models. If vascular markers are not recapitu- binding seen in the transfected cells overexpressing PDGFR
as well as the observed colocalization of RGR with PDGFR inlated in transplant models representing a particular organ-spe-
cific cancer, then aspects of its phenotypic behavior and re- angiogenic islets and tumors. It is interesting to note that a
similar sequence is found in PDGF-D, a related PDGF ligand thatsponse to therapy (particularly targeted antiangiogenic and
antivascular agents) may differ as well. Similar results have been also signals through PDGFR. The sequence RGRS is located in
the secreted PDGF-D at the site of processing from the inactiveseen in the companion study (Hoffman et al., 2003) comparing
de novo epidermal squamous cell carcinomas in the K14-HPV16 to active form of PDGF-D (Bergsten et al., 2001; LaRochelle et
al., 2001).mice with transplant tumors in the adjacent subcutaneous mi-
croenvironment. The additional colocalization of RGR with the endothelial
cell marker MECA32 suggests that an RGR binding moiety is
also expressed by endothelial cells or shared between pericytesHoming peptides revealing molecular anatomy
of tumor vasculature and endothelial cells. While there is no obvious coimmunostain-
ing of either endothelial cell marker (CD31, MECA32) with any ofWe have begun to investigate candidate binding moieties (“re-
ceptors”) for the RIP1-Tag2 homing peptides, initially by search- several pericyte markers (desmin, SMA, NG2) in the angiogenic
islets or tumors (J.J. and G.B., unpublished observations), aing protein databases for proteins that contain the homing pep-
tide sequences and thus might represent the endogenous small subset of FAC-sorted cells within RIP1-Tag2 tumors are
positive for both CD31 and NG2 (G.B., unpublished observa-protein mimicked by the peptide. It is striking that a number
of the candidate proteins revealed by the search have been tions). In addition, both cell types contribute to the vascular
basement membrane and the extracellular matrix that separatesimplicated in some aspect of angiogenesis (PDGFs, WNTs, clau-
dins, collagen XII, FGFR1, Tie-1). We chose to evaluate the and envelops them, and these structures could contain RGR
binding motifs produced by one or both cell type and localizedPDGF-B homology in light of recent evidence implicating PDGF
signaling in the angiogenic phenotype in the RIP-Tag2 model: amongst them. Indeed, purified PDGF-B has been shown to
bind various ECM and BM proteins, including collagens I–IVthree PDGF ligand genes are expressed in the tumor endothelial
cells, while PDGF receptor  is expressed in tumor pericytes (Somasundaram and Schuppan, 1996), laminin-1, nidogen, and
perlecan (Gohring et al., 1998). Another attractive candidate for(Bergers et al., 2003). Pharmacological inhibition of PDGFR sig-
naling in RIP1-Tag2 mice disrupted pericyte association with RGR binding is the predicted prohormone processing enzyme
that binds and cleaves pro-PDGF-B within the RGR homology.the tumor endothelium, inhibited angiogenesis, and reduced
the vascularity of the islet tumors (Bergers et al., 2003). The Interestingly, while the RGR phage and peptide homed effec-
tively to angiogenic progenitor islets and solid tumors in RIP1-results add to a knowledge base implicating PDGF signaling in
pericyte-endothelial cell homeostasis, both in developing ves- Tag2 mice, neither homed to angiogenic dysplasias or tumors
in the HPV16 transgenic mice nor to the MDA-MB-435 subcuta-sels (Betsholtz et al., 2001; Leveen et al., 1994; Lindahl et al.,
1997; Soriano, 1994) and in tumors (Heldin and Westermark, neous tumors. These results suggest that PDGF signaling and
the resultant vessel stabilization by pericytes may differ among1999; Ostman and Heldin, 2001).
The evaluation of RGR in light of its homology to PDGF-B tumors or that there are differences in pericyte activation and/
or maturation (Morikawa et al., 2002). Alternatively, the bloodclearly suggests its homing is associated with PDGFR expres-
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vessels in the squamous cell carcinomas, being less hemor- target. As such, these peptides could be used as biomarkers
or for imaging, particularly of pre-neoplastic lesions, which arerhagic, may limit the accessibility of the blood-borne phage and
labeled peptides to the perivascular cells (see below). notoriously difficult to detect. The peptides homing to angio-
Other homologies between homing peptides and endoge- genic islets, for example, could be used both as markers of
nous proteins listed in Table 1 may also be significant. The fact the angiogenic switch and to monitor therapeutic response to
that many of these proteins have been implicated in angiogen- antiangiogenic agents, in much the same way as parameters
esis, or related biological processes, supports this prediction. such as microvessel density are currently employed. Future
For example, two of the peptides, KAR and VGVA, show homol- experiments will test the efficacy of targeting of imaging agents
ogy to collagen XII, which is associated with blood vessels in and active drugs to multiple stages of tumorigenesis.
the developing embryo (Bohme et al., 1995; Oh et al., 1993). In conclusion, we have used phage display to profile the
Colocalization of both peptides with vascular markers (data not vasculature during the distinctive stages of multistep tumorigen-
shown) is consistent with the predicted localization of colla- esis in a prototypical mouse model of cancer. We have identified
gen XII. three different classes of stage-specific peptides suggestive of
distinctive characteristics of the neovasculature in premalignant
Lessons from profiling different tumor types and malignant lesions. We expect that the selectivity in peptide
It is of interest to compare and contrast the results reported homing will help us understand the stage-specific differences
here to that of the companion study (Hoffman et al., 2003), which in efficacy observed for angiogenesis inhibitor therapy in the
similarly used phage display libraries to profile the angiogenic RIP1-Tag2 model (Bergers et al., 1999). In addition, it may be
dysplasias and squamous cell carcinomas that arise in the skin possible to selectively target antitumor therapies to individual
of K14-HPV16 transgenic mice. That study produced a series or multiple cell types during RIP-Tag tumorigenesis using these
of homing peptides that were selective for angiogenic progeni- homing peptides conjugated to, for example, proapoptotic se-
tors or solid tumors. And again, both tumor type-selective and quences, as previously reported (Ellerby et al., 1999). It will be
tumor-generic phage were identified; their analysis focused on of further interest to ask whether these homing peptides can
skin tumor-specific phage that did not home to the angiogenic similarly characterize the neovasculature of stages in human
vasculature in the stages of pancreatic islet carcinogenesis in pancreatic islet carcinogenesis, as well as in other organ-spe-
RIP1-Tag2 mice. The skin-tumor homing peptides had different cific cancers in mouse models and humans.
sequences from those identified herein, and their candidate
Experimental procedurescellular homologs (and prospective binding moieties) were dis-
tinctive. In sum, each study identified both tumor type-specific
Generation of mice and tissue isolationand stage-specific vascular homing peptides, further supporting
The generation of RIP1-Tag2 mice (Hanahan, 1985) and K14-HPV16 micethe proposition that organ microenvironment imparts distinctive
(Arbeit et al., 1994; Coussens et al., 1996) has been reported. Angiogenic
constraints on neoplastic development that affects the charac- islets were isolated from 8- and 12-week-old RIP1-Tag2 mice by collagenase
teristics of the neovasculature induced to sustain tumor devel- digestion of the excised pancreas and selected based on their red, hemor-
opment and progression. rhagic appearance (Parangi et al., 1995). Tumors were microdissected from
the excised pancreas of 12-week-old RIP1-Tag2 mice and the surroundingIt is intriguing that the two organ sites of neoplastic develop-
exocrine tissue was carefully removed. The synchronicity of tumorigenesisment (skin and pancreas) preferentially selected phage with
in the RIP1-Tag2 model allowed us to simultaneously isolate pools of angio-different cellular specificity. The HPV phage all homed exclu-
genic islets and tumors from the same mouse at 12 weeks of age, thussively to endothelial cells, whereas each of the RIP1-Tag2 phage
affording us the opportunity to directly compare homing of individual phage
representing the three homing classes (angiogenic progenitor, to different stages in an individual mouse/pancreas. Tumors were dissected
tumor, or both) chosen for analysis homed both to pericytes from the ear or chest of K14-HPV16 mice. For the TC3 allograft models,
and to endothelial cells. This suggests significant differences in 106 TC3 tumor cells (Efrat et al., 1988) were inoculated under the skin of
the rear flank of nu/nu mice in a BALB/c background and allowed to growthe vascular morphology and/or functionality in the skin and
until approximately 5 mm in size, and then used for experimental analysis.pancreas. One difference may be in vascular permeability. The
MDA-MB-435 xenograft models were generated by inoculating 106 tumorislet tumors are blood red from hemorrhaging and the angio-
cells subcutaneously in the chest of nu/nu BALB/c mice. Tumors were used
genic vasculature is permeable to a variety of macromolecules for the homing/binding experiments at 8–12 weeks after injection of the
(Hashizume et al., 2000; Thurston et al., 1998). By contrast, the tumor cells. Matrigel plug angiogenesis was induced as previously described
skin tumors are white, indicative of less hemorrhagic vessels (Fulgham et al., 1999; Ngo et al., 2000; Yi et al., 2003). Briefly, 100 l
or higher interstitial pressure. Thus the phage population circu- of Matrigel containing 80 ng/ml bFGF was injected subcutaneously in the
abdominal area of BALB/c/nu/nu mice, and at day 8, the mice were injectedlating through the vascular system in RIP1-Tag2 mice may have
with fluorescein-conjugated peptides as detailed below.had ready access to the perivascular microenvironment,
whereas the “tighter” vessels in the skin lesions may limit such
Phage libraries and library screening
accessibility. Future studies on the expression of the “receptors” The screening process involved two ex vivo selection rounds followed by
identified by these distinctive classes of homing peptides should 2–3 in vivo selection rounds. For the ex vivo selections, cell suspensions
clarify whether their binding moieties are differentially expressed were prepared from the different RIP1-Tag2 lesions in 12-week-old RIP1-
Tag2 mice and incubated overnight at 4C with 109 plaque forming unitsand/or differentially accessible via the vasculature in these dis-
(p.f.u.) of a T7 phage (Novagen) displayed CX7C peptide library. The cellstinctive tumor types and their angiogenic progenitor lesions,
were washed to remove unbound phage and the bound phage rescued andproviding further insight into the dynamics and tissue-specific
amplified in E. coli. This procedure enriches for phage that bind to tumor,qualities of the angiogenic phenotype.
endothelial, and other stromal cells present in the suspension. The ex vivo
The selective accumulation of fluorescein-conjugated pep- pre-selected phage pool was injected intravenously into 12-week-old RIP1-
tides in the RIP-Tag lesions indicates that a monovalent peptide- Tag2 mice through the tail vein, allowed to circulate for 7 min, and heart-
perfused with PBS to remove unbound intravascular phage. As the vascula-receptor interaction is robust enough to carry a payload to the
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from the Department of Defense DAMD 17-02-1-0315 (E.R.) and the N.C.I.is an enrichment of phage that bind to the endothelium of the target tissue.
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